Close Menu
September 15, 2020

Multi-omics in Clinical Cancer Diagnostics: The Importance of RNA-Seq

Genome Webinar

Professor of Cancer Genetics & Surgery, Institute of Cancer and Genomic Sciences
University of Birmingham

Senior Manager of Scientific Affairs,
Lexogen

Colorectal cancer is the third most frequently diagnosed cancer after lung and breast cancer and, unlike these agents, has relatively few stratified molecular targets for therapy due to the complex, heterogenous nature of the disease.

In this webinar, Andrew Beggs of the University of Birmingham will discuss a project that performed stratified analysis of patients as a pre-pilot for the 100,000 Genomes project. His team performed whole-genome sequencing on fresh samples and, as proof of principle, 3’ RNA-seq on matched formalin-fixed, paraffin-embedded samples.

Dr. Beggs will demonstrate that by combining WGS and RNA-seq, many interesting insights can be gained into the underlying disease processes in colorectal cancer, allowing identification of new targets for therapy and disease stratification.

Dr. Lukas Paul, Senior Manager of Scientific Affairs  will talk discuss the acceleration of gene expression profiling projects with the massive multiplexing of 3’ mRNA-Seq libraries.

Sep
24

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.